品牌现货直购
供应商:我要出现这里






查看所有供应商和价格请点击:

68844-77-9生产厂家

68844-77-9价格

68844-77-9

68844-77-9结构式
68844-77-9结构式
  • 常用中文名:阿司咪唑
  • 常用英文名:Astemizole
  • CAS号:68844-77-9
  • 分子式:C28H31FN4O
  • 分子量:458.57
  • 相关类别: 原料药 抗变态反应药 抗组胺药
  • 发布时间:2018-02-20 08:00:00
  • 更新时间:2024-01-03 00:06:36
  • Astemizole 是一个长效的二代抗组胺药物,是常用的抗过敏药物,是组胺H1 受体 (histamine H1-receptor) 的拮抗剂,IC50 值为 4 nM。Astemizole 同时还具有hERG K+通道的阻断活性,IC50 值为0.9 nM。Astemizole 还具有抗胆碱能和止痒作用。

化源商城直购

中文名 阿司咪唑
英文名 astemizole
中文别名 1-(4-氟苄基)-2-(1-[4-甲氧基苯乙基]哌啶-4-基)氨基苯并咪唑
1-[(4-氟苯基)甲基]-N-[1-[2-(4-甲氧苯基)乙基]-4-哌啶基]-1H-苯并咪唑-2-胺
英文别名 Paralergin
1-(4-fluorophenylmethyl)-N-{1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl}-1H-benzimidazol-2-amine
Hismanal(R)
EINECS 272-441-9
Retolen
[3H]-Astemizole
Alermizol
[14C]-Astemizole
Laridal
Astemison
Astemizolum
1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl]benzimidazol-2-amine
Astemizol
Histaminos
Hismanal
1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-1H-benzimidazole-2-amine
描述 Astemizole 是一个长效的二代抗组胺药物,是常用的抗过敏药物,是组胺H1 受体 (histamine H1-receptor) 的拮抗剂,IC50 值为 4 nM。Astemizole 同时还具有hERG K+通道的阻断活性,IC50 值为0.9 nM。Astemizole 还具有抗胆碱能和止痒作用。
相关类别
参考文献

[1]. Laduron PM, et al. In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole. Mol Pharmacol. 1982 Mar;21(2):294-300.

[2]. Richards DM, et al. Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1984 Jul;28(1):38-61.

密度 1.2 g/cm3
沸点 627.3ºC at 760 mmHg
熔点 172.9ºC
分子式 C28H31FN4O
分子量 458.57
闪点 333.2ºC
精确质量 458.24800
PSA 42.32000
LogP 5.36220
外观性状 白色粉末
折射率 1.623
储存条件

存放在密封容器内,并放在阴凉,干燥处。储存的地方必须远离氧化剂。

稳定性

远离氧化物。

水溶解性 DMSO: >20mg/mL
分子结构

1、 摩尔折射率:133.94

2、 摩尔体积(cm3/mol):379.8

3、 等张比容(90.2K):981.0

4、 表面张力(dyne/cm):44.5

5、 极化率(10-24cm3):53.09

计算化学

1.疏水参数计算参考值(XlogP):6

2.氢键供体数量:1

3.氢键受体数量:5

4.可旋转化学键数量:8

5.互变异构体数量:2

6.拓扑分子极性表面积42.3

7.重原子数量:34

8.表面电荷:0

9.复杂度:599

10.同位素原子数量:0

11.确定原子立构中心数量:0

12.不确定原子立构中心数量:0

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

更多

1. 性状:白色结晶。

2. 密度(g/mL,25/4℃):未确定

3. 相对蒸汽密度(g/mL,空气=1):未确定

4. 熔点(ºC):172.9

5. 沸点(ºC,常压):未确定

6. 沸点(ºC,5.2kPa):未确定

7. 折射率:未确定

8. 闪点(ºC):未确定

9. 比旋光度(º):未确定

10. 自燃点或引燃温度(ºC):未确定

11. 蒸气压(kPa,25ºC):未确定

12. 饱和蒸气压(kPa,60ºC):未确定

13. 燃烧热(KJ/mol):未确定

14. 临界温度(ºC):未确定

15. 临界压力(KPa):未确定

16. 油水(辛醇/水)分配系数的对数值:未确定

17. 爆炸上限(%,V/V):未确定

18. 爆炸下限(%,V/V):未确定

19. 溶解性:几乎不溶于水。


Section1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name: Astemizole
CAS-No.: 68844-77-9
Relevant identified uses of the substance or mixture and uses advised against
Identified uses: Laboratory chemicals, Manufacture of substances



Section2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal wordWarning
Hazard statement(s)
H315Causes skin irritation.
H319Causes serious eye irritation.
H335May cause respiratory irritation.
Precautionary statement(s)
P261Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazardnone
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22Harmful if swallowed.
R36/37/38Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36Wear suitable protective clothing.
Other hazards - none

Section3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula: C28H31FN4O
Molecular Weight: 458,57 g/mol
ComponentConcentration
Astemizole
CAS-No.68844-77-9-
EC-No.272-441-9

Section4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

Section5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

Section6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

Section7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Store with desiccant. Light sensitive.
Specific end uses
no data available

Section8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

Section9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) AppearanceForm: solid
b) Odourno data available
c) Odour Thresholdno data available
d) pHno data available
e) Melting point/freezingno data available
point
f) Initial boiling point and no data available
boiling range
g) Flash pointno data available
h) Evaporation rateno data available
i) Flammability (solid, gas) no data available
j) Upper/lowerno data available
flammability or
explosive limits
k) Vapour pressureno data available
l) Vapour densityno data available
m) Relative densityno data available
n) Water solubilityno data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignitionno data available
temperature
q) Decompositionno data available
temperature
r) Viscosityno data available
s) Explosive propertiesno data available
t) Oxidizing propertiesno data available
Other safety information
no data available

Section10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
no data available
Hazardous decomposition products
Other decomposition products - no data available

Section11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
LD50 Oral - rat - > 2.560 mg/kg
Inhalation: Irritating to respiratory system.
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC:No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
Reproductive toxicity - rat - Subcutaneous
Effects on Newborn: Growth statistics (e.g., reduced weight gain). Effects on Newborn: Behavioral. Effects
on Newborn: Physical.
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
InhalationMay be harmful if inhaled. Causes respiratory tract irritation.
IngestionMay be harmful if swallowed.
SkinMay be harmful if absorbed through skin. Causes skin irritation.
EyesCauses serious eye irritation.
Additional Information
RTECS: DD8968000

Section12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

Section13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

Section14. TRANSPORT INFORMATION
UN number
ADR/RID: -IMDG: -IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA:Not dangerous goods
Transport hazard class(es)
ADR/RID: -IMDG: -IATA: -
Packaging group
ADR/RID: -IMDG: -IATA: -
Environmental hazards
ADR/RID: noIMDG Marine pollutant: noIATA: no
Special precautions for user
no data available

Section15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

Section16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

毒理学数据:

急性毒性LD50大鼠(mg/kg):>2560口服。

CHEMICAL IDENTIFICATION

RTECS NUMBER :
DD8968000
CHEMICAL NAME :
Benzimidazole, 1-(p-fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)pi perid-4-yl)amino)-
CAS REGISTRY NUMBER :
68844-77-9
LAST UPDATED :
199703
DATA ITEMS CITED :
14
MOLECULAR FORMULA :
C28-H31-F-N4-O
MOLECULAR WEIGHT :
458.63
WISWESSER LINE NOTATION :
T56 BN DNJ B1R DF& CM- DT6NTJ A2R DO1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
5400 ug/kg
TOXIC EFFECTS :
Behavioral - general anesthetic Cardiac - EKG changes not diagnostic of specified effects Cardiac - pulse rate increase, without fall in BP
REFERENCE :
PECAE5 Pediatric Emergency Care. (Williams & Wilkins, 428 E. Preston St., Baltimore, MD 21202) V.1- 1985- Volume(issue)/page/year: 9,23,1993
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
4 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
REFERENCE :
HUTODJ Human Toxicology. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants., RG 21 2XS, UK) V.1- 1981- Volume(issue)/page/year: 5,43,1986
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
4 mg/kg
TOXIC EFFECTS :
Behavioral - coma Cardiac - arrhythmias (including changes in conduction) Gastrointestinal - nausea or vomiting
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 292,660,1986
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
4 mg/kg
TOXIC EFFECTS :
Cardiac - change in rate
REFERENCE :
JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 31,121,1993
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>2560 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 251,39,1981
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
355 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 33,381,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
28200 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 33,381,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
2560 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 251,39,1981
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1928 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,239,1995
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
35 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,239,1995
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>320 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 251,39,1981
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
21800 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 33,381,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
933 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 251,39,1981 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
220 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - physical
REFERENCE :
CBPCEE Comparative Biochemistry and Physiology, C: Pharmacology, Toxicology and Endocrinology. (Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.74- 1983- Volume(issue)/page/year: 114,123,1996

符号 GHS07
GHS07
信号词 Warning
危害声明 H315-H319-H335
警示性声明 P305 + P351 + P338
危害码 (欧洲) Xn: Harmful;
风险声明 (欧洲) R22;R36/37/38
安全声明 (欧洲) S26-S36
危险品运输编码 UN 2811 6.1 / PGII
WGK德国 3
RTECS号 DD8968000
海关编码 2933990090

化合物(I)和碘甲烷在乙醇中回流8h,环合得到化合物(Ⅱ)。再水解脱去酯基,得到化合物(Ⅲ)。用对甲氧基苯乙基溴进行N-烷基化,得化合物(Ⅳ)。再用对氟苄基溴烷基化,得阿司咪唑。

68844-77-9 preparation

1. 1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮的制备

在反应瓶中加入2-羟基苯并咪唑5.0g(37.3mmol)和NaH 1.6g(53mmol)(NaH含量大约为80%,浸入矿物油中)的DMF 100ml的悬浮液.加毕.在60ºC.(最好有N2保护)搅拌反应1h.再加入4-氟苄基氯(FBC)5.4g(37mmol),加热(60ºC)搅拌反应5.5h.冷却至室温后加入冰水700ml,用二氯甲烷(500ml×2)提取.有机层用食盐水洗.无水Na2SO4干燥.过滤.滤液减压浓缩.剩余物用石油醚析晶.得1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮固体8.0g,为无色结晶mp178~179ºC,收率88%.

2. 1-[(4-氟苯基)甲基]-2-氯苯并咪唑的制备

在反应瓶中加入1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮5.0g(20mmol)和POCl3 28ml(300mmol),搅拌加热回流5.5h.蒸除过量的POCl3,往剩余物加入冷水600ml,用稀氨水(即NH4OH)调至碱性,析出沉淀,过滤收集,用石油醚/二氯甲烷(2:1)重结晶,得无色结晶1-[(4-氟苯基)甲基]-2-氯苯并咪唑4.4g,收率84%,mp75~76ºC.

3. 4-[[1-(4-氟苯基)甲基]-1H苯并咪唑-2-基]氨基]-1-哌啶羧酸乙酯的制备

在反应瓶中加入1-[(4-氟苯基)甲基]-2-氯苯并咪唑3.32g(12.7mmol)和4-氨基-1-哌啶羧酸乙酯4.2g(26.4mmol),在氩气保护下搅拌升温至125 ºC,在该温度搅拌反应5h.冷却后加入10%NaOH水溶液60ml ,混合物用二氯甲烷提取,有机层用食盐水洗,无水Na2SO4干燥,过滤,滤液浓缩至干(减压下),剩余固体用闪式(快速)色谱法提纯,以二氯甲烷洗脱(固体粗品也用二氯甲烷调配进柱) ,得到固体用二氯甲烷/二异丙醚(2:1)重结晶,得4[[1-(4-氟苯基)甲基]-1H苯并咪唑-2-基]氨基]-1-哌啶羧酸乙酯无色结晶2.82g,收率56%,mp179~180ºC.

4. 1-[(4-氟苯基)甲基]-4-(4-哌啶基)-1H-苯并咪唑-2-胺二氢溴酸盐的制备

在反应瓶中加入4-[[1-(4-氟苯基)甲基]-1H苯并咪唑-2-基]氨基]-1-哌啶羧酸乙酯2.1g(5.3mmol)和48%氢溴酸130ml,强烈搅拌下加热,搅拌回流1h.真空下蒸除过量的氢溴酸,剩余物用2-丙醇结晶,得1-[(4-氟苯基)甲基]-4-(4-哌啶基)-1H-苯并咪唑-2-胺二氢溴酸盐2.5g,收率95%,mp280 ºC.

5. 阿司咪唑的合成

在反应瓶中加入1-[(4-氟苯基)甲基]-4-(4-哌啶基)-1H-苯并咪唑-2-胺二氢溴酸盐4.86g(10mmol)、NaH1.2g(80%含量#浸入矿物油中)和KI1.7g(10mmol)悬浮于DMF100ml的悬浮液,搅拌升温至70 ºC(在氩气保护下),在该温度下搅拌反应10h,然后加入4-甲氧基苯乙基氯1.71g(10mmol),连续搅拌加热(60~70 ºC)反应2h.冷却后,加入10%NaOH水溶液100ml,产生沉淀,过滤,用二异丙醚重结晶得阿司咪唑2.3g,收率50%,

68844-77-9 preparation

海关编码 2933990090
中文概述 2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%